Chinese Investor Consortium Buys SciClone But Relisting Possible

 
• By Ying Huang

Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.

Global currency
SciClone Pharmacetuicals Acquired by Chinese Investors

More from China

More from Focus On Asia